MA49635A - Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih - Google Patents

Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih

Info

Publication number
MA49635A
MA49635A MA049635A MA49635A MA49635A MA 49635 A MA49635 A MA 49635A MA 049635 A MA049635 A MA 049635A MA 49635 A MA49635 A MA 49635A MA 49635 A MA49635 A MA 49635A
Authority
MA
Morocco
Prior art keywords
cobicistat
darunavir
emtricitabine
hiv
treatment
Prior art date
Application number
MA049635A
Other languages
English (en)
Inventor
Katia Boven
Smedt Goedele De
Regina Driesen
Dominiek Henrist
Greet Kauwenberghs
Sandeep Mathur
Scott Mccallister
Roel Mertens
Richard Nettles
Magda Opsomer
William Pryz
Vahid Zia
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63168494&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Unlimited Co filed Critical Gilead Sciences Inc
Publication of MA49635A publication Critical patent/MA49635A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA049635A 2017-07-20 2018-07-19 Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih MA49635A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762534885P 2017-07-20 2017-07-20
US201762571384P 2017-10-12 2017-10-12
US201862623174P 2018-01-29 2018-01-29
US201862665339P 2018-05-01 2018-05-01

Publications (1)

Publication Number Publication Date
MA49635A true MA49635A (fr) 2020-05-27

Family

ID=63168494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049635A MA49635A (fr) 2017-07-20 2018-07-19 Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih

Country Status (10)

Country Link
US (1) US10786518B2 (fr)
EP (1) EP3654951A1 (fr)
JP (2) JP2020528409A (fr)
AU (1) AU2018304373A1 (fr)
BR (1) BR112020000842A2 (fr)
CA (1) CA3070713A1 (fr)
CL (1) CL2020000136A1 (fr)
MA (1) MA49635A (fr)
MX (1) MX2020000694A (fr)
WO (1) WO2019018676A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210290590A1 (en) * 2020-03-13 2021-09-23 Janssen Sciences Ireland Unlimited Company Methods of treating subjects infected with hiv
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
HUE035241T2 (en) 2011-07-07 2018-05-02 Janssen Sciences Ireland Uc Darunavir combination products
WO2013004816A1 (fr) 2011-07-07 2013-01-10 Janssen R&D Ireland Formulations de darunavir
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
WO2016108205A1 (fr) * 2015-01-03 2016-07-07 Mylan Laboratories Limited Procédés de préparation d'hémifumarate de ténofovir alafénamide amorphe et d'un prémélange de ce composé

Also Published As

Publication number Publication date
JP2020528409A (ja) 2020-09-24
CA3070713A1 (fr) 2019-01-24
CL2020000136A1 (es) 2020-06-12
US20190022113A1 (en) 2019-01-24
AU2018304373A1 (en) 2020-01-30
US10786518B2 (en) 2020-09-29
WO2019018676A1 (fr) 2019-01-24
BR112020000842A2 (pt) 2020-07-21
JP2023123523A (ja) 2023-09-05
MX2020000694A (es) 2020-07-29
EP3654951A1 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
WO2017106346A3 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA52910A (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA44681A (fr) Administration de b-sarcoglycane et de microarn-29 à l'aide d'un vecteur de virus adéno-associé, et traitement de la dystrophie musculaire
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA47442A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA41996A (fr) Utilisation de triméthazine dans la préparation de médicaments pour la prévention et le traitement de maladies hépatiques
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
MA49635A (fr) Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques